C
Chung-Pin Li
Researcher at Taipei Veterans General Hospital
Publications - 106
Citations - 3509
Chung-Pin Li is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Medicine & Gemcitabine. The author has an hindex of 26, co-authored 86 publications receiving 2913 citations. Previous affiliations of Chung-Pin Li include National Yang-Ming University.
Papers
More filters
Journal ArticleDOI
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam,Chung-Pin Li,György Bodoky,Andrew Dean,Yan Shen Shan,Gayle S. Jameson,Teresa Macarulla,Kyung-Hun Lee,David Cunningham,Jean F Blanc,Richard A Hubner,Chang Fang Chiu,Gilberto Schwartsmann,Jens T. Siveke,Fadi Braiteh,Victor Moyo,Bruce Belanger,Navreet Dhindsa,Eliel Bayever,Daniel D. Von Hoff,Li-Tzong Chen,Li-Tzong Chen +21 more
TL;DR: Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy.
Journal ArticleDOI
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante,Bradley G. Somer,Joon Oh Park,Chung-Pin Li,Chung-Pin Li,Max E. Scheulen,Saifuddin M. Kasubhai,Do-Youn Oh,Yuan Liu,Suman Redhu,Klaudia Steplewski,Ngocdiep Le +11 more
TL;DR: The addition of trametinib to gemcitabine did not improve OS, PFS, ORR or DOR in patients with previously untreated metastatic pancreas cancer, and outcomes were independent of KRAS mutations determined by cfDNA.
Journal ArticleDOI
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study
Chung-Pin Li,Yee Chao,Kwan-Hwa Chi,Wing-Kai Chan,Ho-Chung Teng,Rheun-Chuan Lee,Full-Young Chang,Shou-Dong Lee,Sang-Hue Yen +8 more
TL;DR: GEM C CRT appears more effective than 5-FU CCRT for locally advanced pancreatic cancer and has comparable tolerability.
Journal ArticleDOI
How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based study.
Jack P. Wang,Jack P. Wang,Chen-Yi Wu,Chen-Yi Wu,I-Hsuan Hwang,Chien-Hui Kao,Chien-Hui Kao,Yi-Ping Hung,Yi-Ping Hung,Shinn Jang Hwang,Shinn Jang Hwang,Chung-Pin Li,Chung-Pin Li +12 more
TL;DR: Compared to patients in acute hospital wards, patients with pancreatic cancer in inpatient palliative care units received more frequent pain control treatments, underwent fewer aggressive procedures, and incurred lower medical costs.
Journal ArticleDOI
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
Jin-Shyr Chen,Chiun Hsu,Nai-Jung Chiang,Nai-Jung Chiang,Nai-Jung Chiang,C.S. Tsai,H.-H. Tsou,S.F. Huang,L.-Y. Bai,I.C. Chang,H. S. Shiah,C.-L. Ho,C.-J. Yen,K.-D. Lee,Chang Fang Chiu,Kun-Ming Rau,M.S. Yu,Yali Yang,Ruey Kuen Hsieh,Jang Yang Chang,Jang Yang Chang,Yan Shen Shan,Yee Chao,L.-T. Chen,L.-T. Chen,L.-T. Chen,Wen-Chi Shen,Hung-Chih Hsu,Chih-Hung Hsu,Ying-Chun Shen,Tsang-En Wang,Chung-Pin Li,M.-H. Chen,Wei-Yao Kao,Ping-Ying Chang,Cheng-Chung Wu,Chien-Lin Teng,Chang-Hsien Lu,Shyh-Jer Lin,Being-Whey Wang,Yen-Yang Chen,Yung-Hsin Chin,Tsai-Rong Chung,Wei-Lan Yu,Mei-Hua Lee,Ling-Fang Lin,Pei-Chyi Lin,Ya-Ling Wu,Hui-Ling Wang,Li-Ju Lu,Shiang-Yi Chen,Chih-Chu Wu,Te-Chih Wei +52 more
TL;DR: Addition of cetuximab did not significantly improve the ORR of GEMOX chemotherapy in ABTC, although a trend of PFS improvement was observed, and the trend of improvement did not correlate with KRAS mutation status.